Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

FDA may publicly shame drug makers for thwarting generic rivals

  • Ed Silverman

By Ed Silverman July 19, 2017

Reprints
FDA campus
Andrew Harnik/AP

Attention brand-name drug makers: the Food and Drug Administration may soon publicly shame you for thwarting generic rivals.

The idea is to break a logjam caused by an FDA program that is designed to boost safety.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Where does the female orgasm come from? Scientists think…
Where does the female orgasm come from? Scientists think they know
Under protest, FDA to convene advisory panel to review…
Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
California judge deals GSK a setback as first Zantac…
California judge deals GSK a setback as first Zantac lawsuit will now go to trial

Comments are closed.

Recommended Stories